For complete information about the report, please visit our website
https://www.reportscorner.com/reports/23338/Acorda-Therapeutics---Pipeline-and-Label-Expansion-of-AMPYRA--Drivers-of-Growth---/
Stable sales from marketed products, maturing pipeline and focus on targeting unmet needs in CNS diseases- Acorda (ACOR) has not disappointed its investors (YoY gain of 49.68%). Top-line data from two separate proof-of-concept trials of AMPYRA in treating post-stroke deficits and cerebral palsy (CP) showed improved walking in people with post-stroke deficits and was statistically significant for the timed 25 ft walking measure. ACOR plans to proceed with a pivotal study in post-stroke deficits. Efficacy data from the PhII POC study in CP suggested potential treatment activity on measures of walking and hand strength; however, ACOR is assessing the clinical significance in the setting to decide whether to move AMPYRA forward in this indication. We expect further improvement in Ampyra's sales driven by increase in… For more detail, please read our report released on June 06, 2013, titled, “Acorda Therapeutics - Pipeline and Label Expansion of AMPYRA- Drivers of Growth”.
https://www.reportscorner.com/reports/23338/Acorda-Therapeutics---Pipeline-and-Label-Expansion-of-AMPYRA--Drivers-of-Growth---/
Stable sales from marketed products, maturing pipeline and focus on targeting unmet needs in CNS diseases- Acorda (ACOR) has not disappointed its investors (YoY gain of 49.68%). Top-line data from two separate proof-of-concept trials of AMPYRA in treating post-stroke deficits and cerebral palsy (CP) showed improved walking in people with post-stroke deficits and was statistically significant for the timed 25 ft walking measure. ACOR plans to proceed with a pivotal study in post-stroke deficits. Efficacy data from the PhII POC study in CP suggested potential treatment activity on measures of walking and hand strength; however, ACOR is assessing the clinical significance in the setting to decide whether to move AMPYRA forward in this indication. We expect further improvement in Ampyra's sales driven by increase in… For more detail, please read our report released on June 06, 2013, titled, “Acorda Therapeutics - Pipeline and Label Expansion of AMPYRA- Drivers of Growth”.
No comments:
Post a Comment